Evidence map›Paper›PMID 35528796›Full record

ArticleAsia-Pacific journal of oncology nursing2022

Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment.

Abhishek Shankar, Isaac G Wallbridge, Callum Yau, Deepak Saini, Shubham Roy, Sachidanand Jee Bharati, Seema Mishra, Pritanjali Singh, Tulika Seth

Abstract read
In one paragraph

Article in Asia-Pacific journal of oncology nursing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Beyond tumor biology: nursing interventions for psychological and immune health in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abhishek ShankarDepartment of Radiation Oncology, All India Institute of Medical Sciences, Patna, India.
Isaac G WallbridgeDepartment of Medical Education, University of Sheffield, Sheffield, United Kingdom.
Callum YauDepartment of Medical Education, University of Sheffield, Sheffield, United Kingdom.
Deepak SainiDepartment of Materia Medica, State Lal Bahadur Shastri Homoeopathic Medical College & Hospital, Prayagraj, India.
Shubham RoyIndian Society of Clinical Oncology, Delhi, India.
Sachidanand Jee BharatiDepartment of Oncoanaesthesia and Palliative Medicine, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India.
Seema MishraDepartment of Oncoanaesthesia and Palliative Medicine, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India.
Pritanjali SinghDepartment of Radiation Oncology, All India Institute of Medical Sciences, Patna, India.
Tulika SethDepartment of Clinical Hematology, All India Institute of Medical Sciences, Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of immunotherapy agents has changed the cancer treatment paradigm with better outcomes and lesser side effects. Yet, there are adverse events associated with them. Owing to the increased stimulation of the immune system, the normal homeostatic mechanisms protecting the body from its own immune response can become disrupted, leading to a variety of side effects termed immune-related adverse effects (irAEs). irAEs can have significant associated morbidity and in many cases lead to discontinuation of therapies with unpredictable impact on the course of patients' disease. Few key articles laying out guidelines for the management of irAEs provide general treatment algorithms for the majority of the common irAEs. Nurses should have knowledge of the mechanism and adverse events associated with such therapies. Oncology nurses have a crucial role in identification of irAEs. irAEs may involve multiple systems, and thus, it is necessary to identify and manage these adverse events according to the case these at soon as possible.

Indexed as

CancerImmune checkpoints inhibitorsImmune-related adverse effects (irAEs)ImmunotherapyOncology nurses

Identifiers

PMID35528796
PMCPMC9072166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.